Fertility-Sparing Surgery in Young Women with Ovarian Anaplastic Carcinoma: Two Case Reports and Literature Review Authors: Yuxuan Lin, Dongyan Cao Published: 2026 ABSTRACT AbstractBackgroundOvarian anaplastic carcinoma is rare, typically occurring in elderly women. Cases in young patients who desire fertility preservation are even rarer. More clinical data are required to guide evidence-based management strategies in this specific population. As the International Federation of Gynecology and Obstetrics staging system is the recognized standard for ovarian carcinoma staging, it is applied throughout this work.MethodsWe report two cases of ovarian anaplastic carcinoma in young women (22 and 23 years old) admitted to our hospital, together with a review of five cases (including Case 2 in our report) previously published in patients who underwent fertility-sparing surgery.ResultsThe mean onset age of the patients who underwent fertility-sparing surgery was 22.8 years (range from 17 to 35 years). Except for one patient with stage IIIC disease who died of disease six months after undergoing fertility-sparing surgery, all other patients were diagnosed with stage IA disease. Among the stage IA patients who underwent FSS, two patients were disease-free at a median follow-up of 49.5 months, whereas two patients died of disease with overall survival of 120 and 44 months, respectively.ConclusionOvarian anaplastic carcinoma is a highly aggressive malignant epithelial tumor. Stage seems to be the key prognostic factor. Fertility-sparing surgery is exploratory in this rare disease without sufficient evidence of long-term oncologic safety and should be prudently considered only in carefully selected young patients. Molecular testing should be strongly considered whenever feasible to guide targeted therapy. Larger studies with long-term follow-up are needed to explore the safety of fertility-sparing surgery in this rare malignancy.Keywords: ovarian anaplastic carcinoma, ovarian mucinous borderline tumor, ovarian mucinous carcinoma, fertility-sparing surgery Introduction Ovarian anaplastic carcinoma is a rare, highly aggressive malignant epithelial tumor.1 It always occurs in the setting of a mucinous neoplasm, which may be benign, borderline, or malignant.2 Mural nodules (MNs) are occasionally identified within the wall of a tumor and are classified as benign or malignant.3 Among benign MNs, the sarcoma-like type is the most common, whereas malignant MNs include anaplastic carcinoma, carcinosarcoma, and sarcoma.3 Ovarian anaplastic carcinoma can be further subclassified into rhabdoid, sarcomatoid, and pleomorphic types.3 Although the above three histologic subtypes of ovarian anaplastic carcinoma do not significantly differ in prognosis, they considerably increase the diagnostic difficulty.3 In the most recent World Health Organization (WHO) classification of female genital tract tumors, ovarian anaplastic carcinoma is regarded as a specific morphologic pattern of high‑grade serous carcinoma or other high‑grade carcinomas, rather than a distinct common histologic subtype, which serves as a key reference for clinicopathological diagnosis.2 Nevertheless, when the anaplastic component constitutes the main tumor bulk, both diagnosis and treatment present unique challenges.4 Therefore, a simple diagnosis of “ovarian anaplastic carcinoma” may not be fully accurate in clinical practice. It is important to specify the background (eg, “anaplastic carcinoma arising in an ovarian mucinous tumor” or “ovarian mucinous tumor with anaplastic carcinoma component”) to avoid misclassifying it as a subtype of high‑grade serous carcinoma. Moreover, as the International Federation of Gynecology and Obstetrics (FIGO) staging system is the recognized standard for ovarian carcinoma staging, this system is applied exclusively throughout this work.1 Epidemiologic data indicate that this tumor is extremely rare, with the largest published case series including only 34 patients.3 Among those with advanced‑stage disease, the prognosis is extremely poor, platinum resistance is common, and no standardized treatment regimen is available.3,5 In the Memorial Sloan Kettering Cancer Center (MSKCC) cohort of 13 patients, the platinum‑refractory rate was 38.5% (5/13), and the median overall survival for all patients was only 28.1 months.5 The age range of reported cases is broad, spanning from 154 to 775 years, but occurrence in adolescents and young adults are even rarer, and reports of fertility‑sparing surgery (FSS) in this population are exceptionally scarce. Notably, FSS has been widely accepted for early‑stage epithelial ovarian cancer, but only in patients with low‑risk histologic subtypes, such as low‑grade serous, mucinous, and endometrioid carcinomas.6 The core principle of FSS is to achieve complete tumor resection while preserving the uterus and, when appropriate, one or both adnexa.6 A comprehensive staging procedure is mandatory.6 This includes thorough exploration of the abdominopelvic cavity, collection of peritoneal washing fluid for cytologic examination, resection of all macroscopic suspicious lesions, and multiple peritoneal biopsies.6 Whenever possible, the tumor should be removed intact.6 In cases where the contralateral ovary appears grossly normal, biopsy or incision of the ovary is not recommended, as these procedures may impair ovarian reserve and/or lead to pelvic adhesions.6 However, given the aggressive biologic behavior, rarity of cases and lack of prospective evidence of ovarian anaplastic carcinoma, the feasibility and oncologic safety of FSS in young patients who wish to preserve fertility remain unknown. In a very young patient with apparent stage I disease, the clinician must face a dilemma to balance fertility preservation against the potential risk of undertreatment in a tumor subtype with uncertain behavior. Therefore, accumulating detailed clinical and pathologic data from such rare cases is essential for deepening our understanding of this disease, and for providing real‑world evidence to guide clinical decision‑making. Recent molecular studies have further characterized the genetic landscape of ovarian anaplastic carcinoma. The MSKCC study revealed a key genetic mutation profile in ovarian anaplastic carcinoma: Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutation rate of 80%, Tumor Protein P53 (TP53) mutation rate of 60%, and Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) mutation rate of 60%, confirming a high molecular similarity between ovarian anaplastic carcinoma and ovarian mucinous carcinoma, with KRAS mutation being the core driver event.5 Chapel et al analyzed the molecular relationship between MNs and associated ovarian mucinous tumors, and they found that sarcoma‑like, anaplastic carcinomatous, and sarcomatous nodules represented a morphologic spectrum of clonal neoplasms rather than three discrete biological entities.7 These molecular insights may inform the selection of novel targeted therapies towards ovarian anaplastic carcinoma in the future.7 In this study, we report the clinicopathologic features and treatment courses of two young patients with ovarian anaplastic carcinoma, one of whom underwent FSS, and provide a review of the relevant literature, aiming to offer a reference for clinical practice and to contribute to the limited evidence on fertility preservation in this aggressive histologic type. Case Presentation Case 1: A 22‑year‑old woman presented with intermenstrual bleeding for one year and increased abdominal girth for one week. Her menstrual history was regular (5/30 days), with last menstrual period (LMP) on March 14, 2019. The serum level of Carbohydrate Antigen 125 (CA125) was 20.9 U/mL, Carbohydrate Antigen 19-9 (CA19-9) 60.2 U/mL, and Carcinoembryonic Antigen (CEA) 1.15 ug/L. Pelvic contrast-enhanced magnetic resonance imaging (MRI) revealed a huge cystic mass (26.3×16.5×28.3 cm) in the mid‑lower abdomen. Within the upper part of the cyst, several solid‑cystic masses were attached to the inner surface of the left anterior and posterior walls, measuring 6.1×7.5×10.3 cm and 17.2×6.1×15.3 cm, respectively (Figure 1A and B). Pelvic contrast-enhanced magnetic resonance and pathological images of Case 1. (A) Pelvic enhanced magnetic resonance imaging revealed a huge cystic mass (26.3×16.5×28.3 cm) in the mid‑lower abdomen. (B) Pelvic contrast-enhanced magnetic resonance imaging revealed that several solid‑cystic masses were attached to the inner surface of the left anterior and posterior walls within the upper part of the cyst. (C) The cut surface of the tumor showed solid‑cystic nodules of varying sizes attached to the inner wall. (D) The nodules attached to the inner wall of the tumor showed rich vascularity. (E) Gross pathological examination of the tumor showed that the cystic component measured up to 22 cm in diameter, with wall thickness ranging from 0.2 to 0.9 cm and areas of irregular thickening (1.5–2.2 cm in diameter) (red arrow). (F) Gross pathological examination of the tumor showed that the solid component measured 22×16×6 cm and showed a multilocular and microcystic appearance containing mucinous material, with focal necrosis (black arrow). (G) Microscopic hematoxylin and eosin staining showed that the cyst was lined by gastrointestinal‑type mucinous epithelium with variable degrees of stratification (black arrow). The magnification was 40×. (H) Microscopic hematoxylin and eosin staining showed enlarged hyperchromatic nuclei and focal marked nuclear atypia. Destructive stromal invasion was observed in a small focus (black arrow). The magnification was 40×. (I) Microscopic hematoxylin and eosin staining showed that malignant cells infiltrated the cyst wall, displaying epithelioid and clear cytoplasm, with numerous mitotic figures (black arrows). The magnification was 40×. (J) Microscopic hematoxylin and eosin staining showed that malignant cells infiltrated the cyst wall, displaying spindle‑cell morphologies, with numerous mitotic figures (black arrow). The magnification was 40×. (K) Immunohistochemical displayed that the adenocarcinoma area was positive for CK7 and negative for VIM. The malignant mural nodules area was positive for CK7 and VIM. The magnification was 200×. Abbreviations: CK7, Cytokeratin 7; VIM, Vimentin. On March 20, 2019, the patient underwent transabdominal left adnexectomy. Intraoperatively, a giant tumor originating from the left ovary was found, with an intact capsule. After removal of the left adnexa without cyst rupture or spillage, the cut surface of the tumor showed solid‑cystic nodules of varying sizes attached to the inner wall, with rich vascularity (Figure 1C and D). Frozen section suggested at least a borderline epithelial tumor of the left ovary, with possible focal invasion. Gross pathological examination of the tumor showed a 22×21×7 cm mass with a solid‑cystic cut surface. The cystic component measured up to 22 cm in diameter, with wall thickness ranging from 0.2 to 0.9 cm and areas of irregular thickening (1.5–2.2 cm in diameter) (Figure 1E). The solid component measured 22×16×6 cm and showed a multilocular and microcystic appearance containing mucinous material, with focal necrosis (Figure 1F). Microscopically, the cyst was lined by gastrointestinal‑type mucinous epithelium with variable degrees of stratification, enlarged hyperchromatic nuclei, and focal marked nuclear atypia (Figure 1G and H). Destructive stromal invasion was observed in a small focus (Figure 1H). Malignant cells infiltrated the cyst wall, displaying epithelioid, clear cytoplasm, and spindle‑cell morphologies, with numerous mitotic figures (Figure 1I and J). Immunohistochemical (IHC) results were as follows (Figure 1K). In the adenocarcinoma area, P53 showed a missense mutation pattern, and Cytokeratin (CK) 7, Paired Box Gene 8 (PAX8), and villin were positive; Ki‑67 was 30% positive; CK20 and Caudal Type Homeobox 2 (CDX2) were partially positive; Estrogen Receptor (ER), Progesterone Receptor (PR), Vimentin (VIM), and Wilms’ Tumor 1 (WT1) were negative. In the MNs area, CK7, PAX8, CK, and VIM were positive; Ki‑67 was 60% positive; CK20, CDX2, Cluster of Differentiation 10 (CD10), Smooth Muscle Actin (SMA), Desmin, and WT1 were negative; P53 showed a missense mutation pattern, and P16 was positive. The pathological diagnosis was left ovarian mucinous borderline tumor with focal moderately differentiated adenocarcinoma, and malignant MNs (anaplastic carcinoma). On April 16, 2019, the patient underwent laparoscopic ovarian cancer staging surgery, including total hysterectomy, right adnexectomy, pelvic and para‑aortic lymphadenectomy, omentectomy, appendectomy and multiple peritoneal biopsies. Pathological examination revealed no tumor involvement in the uterus, right adnexa, omentum, appendix, peritoneal washings and multiple peritoneal biopsies. However, metastatic tumor was identified in the left common iliac lymph node (1/1), with morphology consistent with metastasis from the anaplastic carcinoma MNs. The final diagnosis was left ovarian mucinous adenocarcinoma with anaplastic carcinoma component, FIGO stage IIIA1. Postoperatively, the patient received three cycles of paclitaxel plus carboplatin (TC) on April 23, May 16, and June 6, 2019. During this period, CA125, CA19-9 and CEA levels remained within normal ranges (Figure 2A–C). On June 24, 2019, chest-abdomen-pelvis contrast-enhanced computed tomography (CT) showed multiple para‑aortic lymph nodes arranged in a beaded pattern, with the largest measuring approximately 0.9 cm in short axis. The patient continued to receive two another cycles of TC regimen on June 27 and July 19, 2019. However, CA125 levels began to climb up (Figure 2A). On August 7, 2019, positron emission tomography‑CT (PET-CT) revealed multiple metastatic lymph nodes (with the largest diameter of 1.5 cm) around the abdominal aorta at the level of both kidneys. The patient was considered platinum‑refractory. The chemotherapy regimen was then switched to oxaliplatin plus 5‑fluorouracil plus oxaliplatin (FOLFOX) for two cycles on August 26 and September 9, 2019, referring to treatment protocols for gastrointestinal mucinous carcinoma. Nevertheless, CA125 and CEA levels continued to increase (Figure 2A and C). Repeat contrast-enhanced CT showed soft tissue density around the para‑aortic region and bilateral common iliac arteries, with the largest lesion measuring 3.8×3.0 cm, indicating persistent disease progression. From October to November 2019, local radiotherapy was delivered to the metastatic lesions in the para‑aortic and bilateral common iliac regions. Thereafter, the patient’s general condition progressively deteriorated, and all anti-cancer treatments were discontinued. On February 1, 2020, the patient died of tumor progression, only 11 months after her initial surgery. Changes of different tumor biomarkers at different treatment points in Case 1. (A) Changes in serum levels of CA125 at different treatment points. (B) Changes in serum levels of CA19-9 at different treatment points. (C) Changes in serum levels of CEA at different treatment points. Abbreviations: CA125, Carbohydrate Antigen 125; CA19-9, Carbohydrate Antigen 19-9; CEA, Carcinoembryonic Antigen; TC, Paclitaxel+Carboplatin; FOLFOX, Folinic acid+5-Fluorouracil+Oxaliplatin. Case 2: A 23‑year‑old woman presented with abdominal distension for six months. Her menstrual history was regular (7/30–35 days), with LMP on July 1, 2021. The serum level of CA125 was 31.03 U/mL, CA19‑9 183.10 U/mL and CEA 3.81ug/L. Chest-abdomen-pelvis contrast-enhanced CT showed a huge multilocular cystic mass (32.6×29.3×16.0 cm) in the abdominopelvic cavity, closely related to the left ovarian vascular pedicle. Multiple septa were visible within the mass, with marked enhancement of the cyst wall and septa after contrast administration (Figure 3A and B). Chest-abdomen-pelvis contrast-enhanced computed tomography and pathological images of Case 2. (A) Chest-abdomen-pelvis contrast-enhanced computed tomography showed a huge multilocular cystic mass (32.6×29.3×16.0 cm) in the abdominopelvic cavity, closely related to the left ovarian vascular pedicle. [A], Anterior; [P], Posterior. (B) Chest-abdomen-pelvis contrast-enhanced computed tomography showed that multiple septa were within the mass, with marked enhancement of the cyst wall and septa after contrast administration. [H], Head; [F], Foot. (C) The cut surface of the tumor showed a multilocular cyst with a mucinous inner wall. Coffee‑colored material was attached to part of the inner wall, but no distinct papillary structures were seen. (D) Microscopic hematoxylin and eosin staining showed that the cyst was lined by gastrointestinal‑type mucinous epithelium (black arrow). The magnification was 200×. (E) Microscopic hematoxylin and eosin staining showed enlarged hyperchromatic nuclei and focal marked nuclear atypia (black arrows). The magnification was 200×. The nature of the pelvic mass remained indeterminate before surgery, and the patient expressed a clear preference to preserve ovarian function and fertility regarding the choice of initial surgical procedure. After thorough discussion of the potential risks including the possibility of an undiagnosed malignancy, tumor rupture, tumor dissemination, the risk of recurrence, and the need for subsequent staging surgery, the patient provided written informed consent for cystectomy rather than adnexectomy. On July 15, 2021, the patient underwent transabdominal left ovarian cystectomy. Intraoperatively, the left ovary was found to be solid‑cystically enlarged, measuring approximately 35 cm in diameter, with an intact capsule. The cyst was carefully exteriorized, and cystectomy was performed with saline gauze protection of the surrounding peritoneal cavity. No intraoperative rupture, cyst spillage, or capsular compromise occurred during the procedure. After removal, the cut surface of the tumor showed a multilocular cyst with a mucinous inner wall. Coffee‑colored material was attached to part of the inner wall, but no distinct papillary structures were seen (Figure 3C). Frozen section of the left ovarian cyst suggested a mucinous epithelial tumor, benign in nature. Postoperative pathological examination revealed a borderline mucinous tumor of the left ovary with a focal MNs of anaplastic carcinoma (Figure 3D and E). IHC results were as follows. In the adenocarcinoma area, ER, PR, and VIM were negative; P53 showed a missense mutation pattern; Ki‑67 was focally 10% positive; P16 was positive; CK7 was mostly positive; CK20 was partially positive; CA125 was focally positive; PAX8 was partially weakly positive; and CDX2 was focally positive. In the malignant MNs area, CK was partially positive, VIM was positive, CD34 highlighted blood vessels, Ki‑67 was 30% positive, CK7 was positive, P53 showed a missense mutation pattern, and P16 was positive. Subsequently, the surgical options—including radical surgery (total hysterectomy, bilateral salpingo‑oophorectomy, lymphadenectomy, omentectomy, appendectomy and peritoneal biopsies) and FSS (based on a comprehensive staging procedure, the uterus and one healthy adnexa could be preserved)—were thoroughly discussed with the patient prior to the procedure. The potential benefits, risks, and possible oncological outcomes of each approach were explained in detail, with particular emphasis on the uncertainty of fertility preservation in the context of this rare and aggressive tumor. After full deliberation, the patient expressed a strong desire to preserve fertility and provided written informed consent specifically for the FSS procedure. The surgical plan was subsequently confirmed by a multidisciplinary team comprising gynecologic oncologists, reproductive medicine specialists, and pathologists. On August 19, 2021, the patient underwent laparoscopic fertility‑sparing ovarian cancer staging surgery, including left adnexectomy, right ovarian biopsy, pelvic and para‑aortic lymphadenectomy, omentectomy, appendectomy and multiple peritoneal biopsies. Pathological examination showed no tumor in the left adnexa, right ovarian biopsy tissue, omentum, appendix, lymph nodes, peritoneal washings and peritoneal biopsies. The final diagnosis was left ovarian borderline mucinous tumor with anaplastic carcinoma component, FIGO stage IA. The patient subsequently received four cycles of TC regimen. The changes in tumor markers during treatment are shown in Figure 4A–C. After completing chemotherapy in November 2021, the patient was followed up until February 2026 (4 years and 3 months) and showed no signs of tumor recurrence. Regarding reproductive outcomes, the patient resumed regular menstruation five months after the completion of chemotherapy. Recent assessment of ovarian reserve showed an anti‑Müllerian hormone (AMH) level of 4.7 ng/mL on 12 February 2026, indicating preserved ovarian function. Regarding reproductive counseling, the patient is currently unmarried and has no male partner. She does not have an immediate desire for childbearing and therefore does not seek or undergo any fertility preservation procedures (such as oocyte or embryo cryopreservation) prior to or after chemotherapy. No further reproductive interventions have been undertaken to date. Changes of different tumor biomarkers at different treatment points in Case 2. (A) Changes in serum levels of CA125 at different treatment points. (B) Changes in serum levels of CA19-9 at different treatment points. (C) Changes in serum levels of CEA at different treatment points. Abbreviations: CA125, Carbohydrate Antigen 125; CA19-9, Carbohydrate Antigen 19-9; CEA, Carcinoembryonic Antigen; TC, Paclitaxel+Carboplatin. Discussion In this study, we report two cases of ovarian anaplastic carcinoma occurring in young women (22 and 23 years old, respectively). Both patients presented with non‑specific symptoms such as abdominal pain, distension, irregular vaginal bleeding and a huge abdominopelvic mass. At initial diagnosis, tumor marker levels showed elevated CA19‑9 with normal or mildly elevated CA125, a profile similar to that of ovarian mucinous neoplasms. Pathologically, both anaplastic carcinomas arose unilaterally in the setting of a mucinous tumor (malignant tumor in Case 1 and borderline tumor in Case 2). The tumors were large with a solid‑cystic cut surface. The solid areas exhibited extensive hemorrhage, necrosis, and cystic change. Unlike typical ovarian serous carcinoma, no obvious papillary structures were seen in either tumor. Microscopically, the tumor cells were highly undifferentiated, with marked pleomorphism, numerous mitotic figures, poor cell cohesion, and scant stroma. Immunohistochemically, both cases showed a missense mutation pattern of P53 in the malignant MNs area, along with a dual‑positive pattern (VIM positive together with CK positive or partially positive). This dual positivity is the key immunohistochemical feature that distinguishes ovarian anaplastic carcinoma from other types of MNs (eg, sarcoma-like type and true sarcoma type, which are always VIM‑positive but CK‑negative).8,9 However, VIM expression within the tumor may be heterogeneous: some cells are strongly positive while others are weakly positive or negative, reflecting the degree of dedifferentiation.10 The prognosis differed markedly between the two patients. Case 1 (FIGO stage IIIA1) was platinum‑refractory to first‑line TC regimen. The subsequent FOLFOX regimen and local radiotherapy still failed to control disease progression, and overall survival was only 11 months. Case 2 (FIGO stage IA) underwent FSS followed by four cycles of TC regimen and has remained recurrence‑free for nearly five years, indicating a favorable outcome. Our two cases provide complementary information on the prognostic trajectory of young patients with ovarian anaplastic carcinoma at different stages. Patient in Case 2 underwent FSS, providing real‑world evidence for fertility preservation in such patients. The characteristics of our two cases are highly consistent with the findings of the 34‑case series by Provenza et al3 and the MSKCC cohort by Sullivan et al5 Although the age of our patients (22 and 23 years) is much younger than the reported median ages (44 years3 and 39 years5), it falls within the broad age range of the disease and its occasional occurrence in young individuals. Regarding the relationship between stage and prognosis, previous reports have consistently shown that earlier stage is associated with better outcome. Provenza et al reported that all ten stage IA patients were disease‑free at a median follow‑up of 5 years, whereas seven patients (three stage IC, one stage II, one stage III, and one stage IV) died of disease with a median time to death of only 8 months.3 In the MSKCC cohort, all five stage I patients (three stage IA, two stage IC) were disease‑free at a median follow‑up of 42 months.5 The median overall survival for stage III and stage IV patients was 15.6 months and 7.1 months, respectively, and the platinum‑refractory rate was 38.5%.5 Neither of these two large studies performed a subgroup analysis of stage I patients.3,5 The raw data from Provenza et al showed a mortality rate of 50% for stage IC versus 0% for stage IA, but the small sample size and lack of a P‑value preclude a formal comparison.3 In the MSKCC cohort, the number of stage I patients was too small for subgroup analysis, and the similarly good outcomes in stage IA and IC patients may be explained by the predominance of stage IC1 subtype and the limited case numbers.5 Notably, the MSKCC cohort reported a high rate of TP53 mutations in the MNs area, and this was consistently reflected in both of our cases, which exhibited a P53 missense mutation pattern.5 To further explore the FSS conducted in patients with this rare tumor, we performed a literature search on June 2, 2026, using the PubMed, Embase, Web of Science, Cochrane Library and Scopus database. The search terms and Boolean operators were as follows: “ovarian” AND “mural nodules” [Title/Abstract]. Given the rarity of this entity and the heterogeneous terminology used in the literature, we also manually screened the reference lists of retrieved articles and relevant reviews to identify additional cases that might have been described under alternative terms, such as “malignant mural nodules”, “sarcomatoid carcinoma”, “rhabdoid carcinoma” or “mucinous tumors with anaplastic nodules”. The inclusion criteria were: (1) pathologically confirmed ovarian anaplastic carcinoma; (2) patients who underwent FSS; (3) sufficient clinical and follow‑up data available. The exclusion criteria were: (1) cases of sarcoma‑like MNs (benign); (2) cases of carcinosarcoma; (3) cases of sarcoma; (4) duplicate reports from the same institution or overlapping patient cohorts. Duplicate publications were identified by comparing author names, institutional affiliations, and reported case details. Only the most complete or most recent report was retained. Case selection and data extraction were performed independently by two reviewers, and any discrepancies were resolved through discussion. Through this process, we identified five patients (including Case 2 in our report) who underwent FSS.11–14 The detailed information of these five patients was summarized in Table 1. The mean onset age of these five patients was 22.8 years (range from 17 to 35 years). Except for one patient with stage IIIC disease who died of disease six months after undergoing FSS, all other patients were diagnosed with stage IA disease. Strikingly, among the stage IA patients who underwent FSS, two patients died of disease with overall survival of 120 and 44 months, respectively. This finding is particularly noteworthy because stage IA represents the most favorable prognostic group, and yet mortality occurred even in these presumably low‑risk patients. The remaining two stage IA patients were disease‑free at a median follow‑up of 49.5 months. Taken together, these data suggest that even early‑stage ovarian anaplastic carcinoma can behave aggressively, and the decision to perform FSS should be made with extreme caution, with full acknowledgment of the potential for adverse outcomes despite early diagnosis. However, molecular features and reproductive outcomes were unavailable for most cases, preventing an assessment of the relationship between FSS safety and these features. Table 1Literature Review of Patients with Ovarian Anaplastic Carcinoma Who Underwent Fertility-Sparing SurgeryAuthorAge (Years)FIGO StageHistology SettingMNs (Type, Number, Size)SurgeryChemotherapy Regimens (Cycles)Follow-up (Months)Recurrence SiteFertility OutcomesMolecular DataYamana et al (1984)1118IAMucinous adenocarcinomaPleomorphic, - (-)USONone120 (DOD)Out of pelvis (multiple)UnavailableUnavailableShao et al (2020)1221IAMucinous adenocarcinomaPleomorphic, 2 (4*5*5cm and 3*1*0.8cm)USO+OM+A+PLNDCisplatin+cyclophosphamide (2)44 (DOD)UnavailableG0P0KRAS mutationZou et al (2021)1335IIICMucinous adenocarcinomaUnavailableUSO +OM+A+PLNDCarboplatin+docetaxel (3)6 (DOD)Out of pelvis (multiple)G0P0UnavailableHuang et al (2022)1417IAMucinous borderline tumorPleomorphic, Multiple (2.5–4.5cm in diameter)USO+OM+APaclitaxel+carboplatin (6)48 (NED)–UnavailableUnavailableCase 2 in our study23IAMucinous borderline tumorPleomorphic, 1 (1.7*1.3*0.5cm)USO+OM+A+PLNDPaclitaxel+carboplatin (4)51 (NED)–G0P0UnavailableAbbreviations: A, appendectomy; DOD, died of disease; FIGO, International Federation of Gynecology and Obstetrics; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; NED, no evidence of disease; OM, omentectomy; PLND, pelvic lymph node dissection; USO, unilateral salpingo-oophorectomy. Literature Review of Patients with Ovarian Anaplastic Carcinoma Who Underwent Fertility-Sparing Surgery Abbreviations: A, appendectomy; DOD, died of disease; FIGO, International Federation of Gynecology and Obstetrics; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; NED, no evidence of disease; OM, omentectomy; PLND, pelvic lymph node dissection; USO, unilateral salpingo-oophorectomy. There has been no standardized treatment regimen for ovarian anaplastic carcinoma till now. Current management generally follows the principles for high‑grade serous ovarian carcinoma, including comprehensive staging or cytoreductive surgery followed by adjuvant platinum‑based chemotherapy plus paclitaxel.1 Optimal surgery is essential, even for patients with advanced disease. For stage IA patients, whether they should receive adjuvant chemotherapy remains controversial. Although some of the stage IA patients have remained disease‑free without adjuvant chemotherapy, definitive conclusions cannot be drawn due to the lack of prospective evidence.3 However, for patients with advanced disease, platinum resistance is common. The absence of standardized chemotherapy protocols means that most clinicians refer to regimens used for high‑grade serous or mucinous ovarian cancer. Moreover, disease progression is extremely rapid in advanced‑stage patients, which also greatly compresses the time window for chemotherapy evaluation and decision‑making, and the rapid deterioration of performance status often precludes attempts at targeted therapy or clinical trials. To conclude, the highly aggressive nature of this tumor poses significant therapeutic challenges mentioned above. Regarding FSS, evidence for its application in the rare and highly aggressive anaplastic carcinoma subtype is insufficient. Based on literature review mentioned above and the guidelines from European Society of Gynaecological Oncology (ESGO), European Society of Human Reproduction and Embryology (ESHRE), and European Society for Gynaecological Endoscopy (ESGE), we interpret that FSS should be prudently considered only in carefully selected young patients (generally those younger than 40 years) with stage IA or IC1 ovarian anaplastic carcinoma, a background of benign/borderline mucinous tumor or expansile mucinous carcinoma, a strong desire for fertility preservation, appropriate fertility potential, and after complete staging, expert pathology review, multidisciplinary discussion and fully informed consent.6 However, it must be re-emphasized that FSS remains exploratory in this rare disease without sufficient evidence of long-term oncologic safety, and requires extremely prudent consideration and shared decision‑making between the patient and the physician in clinical practice. Several limitations of this study should be acknowledged. First, the retrospective design and small sample size precludes definitive conclusions driven from our study. Second, the absence of molecular testing limits our ability to correlate outcomes with genetic alterations. Third, the literature review was not systematic, potentially introducing selection and publication bias, and the heterogeneous terminology used across published cases may have led to incomplete retrieval. Fourth, the follow‑up for reproductive outcomes after FSS is limited, and no subsequent pregnancies or fertility treatments have been undertaken in Case 2. Finally, as a single‑center report, selection bias and individualized treatment decisions are unavoidable. In summary, ovarian anaplastic carcinoma is a highly aggressive tumor closely associated with ovarian mucinous neoplasms. Stage seems to be the key determinant of prognosis. Platinum resistance is common. For advanced‑stage disease, more intensive upfront treatment strategies may be worth considering, and the role of FOLFOX regimen as adjuvant chemotherapy deserves further exploration. Molecular testing may help identify new therapeutic directions. For patients diagnosed with this rare disease, especially those with advanced disease, molecular testing for genes, particularly for KRAS and TP53, can be considered both to improve biological characterization and to identify potential therapeutic options. We also strongly advocate for the establishment of national or international databases to systematically collect clinical, pathological, and molecular data, thereby providing a basis for future standardization of treatment strategies. In addition, larger multicenter studies or collaborative case series with long‑term follow‑up are urgently needed to better define appropriate patient selection criteria for FSS, as well as to evaluate the oncologic safety and reproductive outcomes of FSS in this rare malignancy. Conclusion Ovarian anaplastic carcinoma is a rare, highly aggressive malignant epithelial tumor. Stage seems to be the key prognostic factor in ovarian anaplastic carcinoma: early-stage disease appears to be associated with better outcomes, although recurrence and death have been reported even in stage IA cases, while advanced‑stage disease shows rapid progression and platinum resistance. FSS is exploratory in this rare disease without sufficient evidence of long-term oncologic safety and should be prudently considered only in carefully selected young patients. Molecular testing should be strongly considered whenever feasible, both to improve biological characterization and to identify potential therapeutic options. Larger multicenter studies or collaborative case series with long‑term follow‑up are needed to explore the safety of FSS in this rare malignancy. Funding Statement The authors declare that no funds, grants, or other support were received during the preparation of this paper. Abbreviations A, Appendectomy; AMH, Anti‑Müllerian Hormone; CA125, Carbohydrate Antigen 125; CA19-9, Carbohydrate Antigen 19-9; CD10, Cluster of Differentiation 10; CDKN2A, Cyclin-Dependent Kinase Inhibitor 2A; CDX2, Caudal Type Homebox 2; CEA, Carcinoembryonic Antigen; CK, Cytokeratin; CT, Computed Tomography; DOD, Died of Disease; ER, Estrogen Receptor; ESGE, European Society for Gynaecological Endoscopy; ESGO, European Society of Gynaecological Oncology; ESHRE, European Society of Human Reproduction and Embryology; FIGO, International Federation of Gynecology and Obstetrics; FOLFOX, Folinic acid+5-Fluorouracil+Oxaliplatin; FSS, Fertility‑Sparing Surgery; IHC, Immunohistochemical; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; LMP, Last Menstrual Period; MNs, Mural Nodules; MRI, Magnetic Resonance Imaging; MSKCC, Memorial Sloan Kettering Cancer Center; NED, No Evidence of Disease; OM, Omentectomy; PAX8, Paired Box Gene 8; PET-CT, Positron Emission Tomography‑ Computed Tomography; PLND, Pelvic Lymph Node Dissection; PR, Progesterone Receptor; SMA, Smooth Muscle Actin; TC, Paclitaxel+Carboplatin; TP53, Tumor Protein 53; USO, Unilateral Salpingo-Oophorectomy; VIM, Vimentin; WHO, World Health Organization; WT1, Wilms’ Tumor 1. Data Sharing Statement The datasets generated used and/or analyzed during the current study are available from the corresponding author on reasonable request. Ethics Approval and Consent to Participate This study was approved by the Ethical Committee of Peking Union Medical College Hospital. The approval number was K24C2998 (approved on 13th September 2024). Written informed consent was obtained for participation in this study. Consent for Publication Written informed consent was obtained from the two patients for publication of this case report and the accompanying images. A copy of the written informed consent is available upon request. The Ethical Committee of Peking Union Medical College Hospital approved to publish this case report and the accompanying images. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare that they have no competing interests. References Associated Data Data Availability Statement The datasets generated used and/or analyzed during the current study are available from the corresponding author on reasonable request.